Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1992-11-27
|
pubmed:abstractText |
The effects of systemic administration (i.p.) of dynorphin A(1-13) on the cocaine-induced behavioural alterations in the mouse were determined by using multi-dimensional behavioural analyses, based upon a capacitance system. A 1.0 mg/kg dose of cocaine did not influence behaviour, while increasing doses to 3-30 mg/kg produced a significant increment in the frequency of behaviour, such as linear locomotion, circling, rearing and grooming. Although a 1.0 mg/kg dose of dynorphin A(1-13) alone produced a significant decrease in grooming behaviour, larger doses (3.0 and 10.0 mg/kg) of the peptide failed to affect different behaviour. The cocaine (3.0 mg/kg)-induced increases in linear locomotion, circling and rearing behaviour were significantly inhibited by dynorphin A(1-13) (10.0 mg/kg). The inhibitory effects of dynorphin A(1-13) (10.0 mg/kg) were antagonized by the opioid antagonist Mr 2266 (5.6 mg/kg). It is thus possible that the systemic administration of dynorphin A(1-13) inhibits different behavioural responses induced by cocaine through the blood-brain barrier, although the instability of amino acid bonds or the relatively large molecular weight of dynorphin A(1-13), may result in the failure to demonstrate opioid activity by the peptide after systemic administration.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics,
http://linkedlifedata.com/resource/pubmed/chemical/Benzomorphans,
http://linkedlifedata.com/resource/pubmed/chemical/Cocaine,
http://linkedlifedata.com/resource/pubmed/chemical/Dynorphins,
http://linkedlifedata.com/resource/pubmed/chemical/MR 2266,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotic Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/dynorphin (1-13)
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0028-3908
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
843-9
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1359442-Analgesics,
pubmed-meshheading:1359442-Animals,
pubmed-meshheading:1359442-Behavior, Animal,
pubmed-meshheading:1359442-Benzomorphans,
pubmed-meshheading:1359442-Cocaine,
pubmed-meshheading:1359442-Dynorphins,
pubmed-meshheading:1359442-Injections, Intraperitoneal,
pubmed-meshheading:1359442-Male,
pubmed-meshheading:1359442-Mice,
pubmed-meshheading:1359442-Mice, Inbred Strains,
pubmed-meshheading:1359442-Motor Activity,
pubmed-meshheading:1359442-Narcotic Antagonists,
pubmed-meshheading:1359442-Peptide Fragments,
pubmed-meshheading:1359442-Substance Withdrawal Syndrome
|
pubmed:year |
1992
|
pubmed:articleTitle |
Systemic administration of dynorphin A(1-13) markedly inhibits different behavioural responses induced by cocaine in the mouse.
|
pubmed:affiliation |
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Meijo University, Nagoya, Japan.
|
pubmed:publicationType |
Journal Article
|